

Charles M. Lizza
William C. Baton
Sarah A. Sullivan
SAUL EWING ARNSTEIN & LEHR LLP
One Riverfront Plaza, Suite 1520
Newark, NJ 07102-5426
(973) 286-6700
clizza@saul.com

*Attorneys for Plaintiffs
Mitsubishi Tanabe Pharma Corp.,
Janssen Pharmaceuticals, Inc., Janssen
Pharmaceutica NV, Janssen Research
and Development, LLC, and Cilag
GmbH International*

**UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY**

MITSUBISHI TANABE PHARMA
CORPORATION, JANSSEN
PHARMACEUTICALS, INC., JANSSEN
PHARMACEUTICA NV, JANSSEN
RESEARCH AND DEVELOPMENT, LLC,
and CILAG GMBH INTERNATIONAL,

Plaintiffs,

v.

SANDOZ INC., *et al.*,

Defendants.

**Civil Action No. 17-5319 (FLW)(DEA)
(consolidated)**


ORDER

(Filed Electronically)

This matter having come before the Court by a stipulation between Plaintiffs Mitsubishi Tanabe Pharma Corp., Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, Janssen Research and Development, LLC, and Cilag GmbH International (collectively, "Plaintiffs") and Defendant Zydus Pharmaceuticals (USA) Inc. ("Zydus"); and the Court having considered the stipulation and the provisions set forth therein; and for good cause shown,

IT IS ON THIS 24th day of April, 2020,

ORDERED that the statutory stay of U.S. Food and Drug Administration (“FDA”) approval of Zydus’s ANDA Nos. 210541 and 210542 is hereby extended from September 29, 2020, until one-hundred and twenty (120) days from the conclusion date of the trial in the above-captioned action. Zydus shall notify the FDA of this Order within five business days after its entry by the Court. Zydus shall further notify the FDA of the conclusion of the trial within five business days after the conclusion date.



Hon. Freda L. Wolfson, U.S.D.J.